Toward genome editing in X-linked RP-development of a mouse model with specific treatment relevant features
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Authors
Schlegel, J.Hoffmann, J.
Roll, D.
Muller, B.
Gunther, S.
Zhang, Wei
Janise, A.
Vossing, C.
Fuhler, B.
Neidhardt, J.
Khanna, Hemant
Lorenz, B.
Stieger, K.
UMass Chan Affiliations
Department of OphthalmologyDocument Type
Journal ArticlePublication Date
2019-01-01Keywords
genome editingretina
neurons
mouse model
endonucleases
Amino Acids, Peptides, and Proteins
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Enzymes and Coenzymes
Eye Diseases
Genetics and Genomics
Molecular and Cellular Neuroscience
Nucleic Acids, Nucleotides, and Nucleosides
Ophthalmology
Translational Medical Research
Metadata
Show full item recordAbstract
Genome editing represents a powerful tool to treat inherited disorders. Highly specific endonucleases induce a DNA double strand break near the mutant site, which is subsequently repaired by cellular DNA repair mechanisms that involve the presence of a wild type template DNA. In vivo applications of this strategy are still rare, in part due to the absence of appropriate animal models carrying human disease mutations and knowledge of the efficient targeting of endonucleases. Here we report the generation and characterization of a new mouse model for X-linked retinitis pigmentosa (XLRP) carrying a point mutation in the mutational hotspot exon ORF15 of the RPGR gene as well as a recognition site for the homing endonuclease I-SceI. Presence of the genomic modifications was verified at the RNA and protein levels. The mutant protein was observed at low levels. Optical coherence tomography studies revealed a slowly progressive retinal degeneration with photoreceptor loss starting at 9 months of age, paralleling the onset of functional deficits as seen in the electroretinogram. Early changes to the outer retinal bands can be used as biomarker during treatment applications. We further show for the first time efficient targeting using the I-SceI enzyme at the genomic locus in a proof of concept in photoreceptors following adeno-associated virus mediated gene transfer in vivo. Taken together, our studies not only provide a human-XLRP disease model but also act as a platform to design genome editing technology for retinal degenerative diseases using the currently available endonucleases.Source
Transl Res. 2019 Jan;203:57-72. doi: 10.1016/j.trsl.2018.08.006. Epub 2018 Aug 24. Link to article on publisher's site
DOI
10.1016/j.trsl.2018.08.006Permanent Link to this Item
http://hdl.handle.net/20.500.14038/40925PubMed ID
30213530Related Resources
Rights
Copyright 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Distribution License
http://creativecommons.org/licenses/by-nc-nd/4.0/ae974a485f413a2113503eed53cd6c53
10.1016/j.trsl.2018.08.006
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

